“Real-world” effectiveness of daily controller medicine in children with mild persistent asthma

Bukstein, Don A.; Luskin, Allan T.; Bernstein, Avi J.

doi:10.1016/s1081-1206(10)61848-0

Cited by 69 publications

(41 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies were from the USA. The included studies mainly used a cohort design (n=19), with the remainder utilising a cross-sectional (n=1) [9], case-control (n=1) [30] or randomised design (n=2) [24,40]. Studies analysed adherence rates over a follow-up period ranging from 13 weeks [9] to 4 years [40].…”

Section: Overview Of the Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Medication adherence and the risk of severe asthma exacerbations: a systematic review

et al. 2014

View full text Add to dashboard Cite

The benefits of drug therapy for asthma have been well established, but adherence to treatment is poor, and this might be associated with an increased risk of asthma exacerbations. The aim of this study was to review the literature on the association between adherence to asthma controller treatment and risk of severe asthma exacerbations in children and adults.A systematic literature search was performed in PubMed, Embase and Web of Science, from inception until January 2014. Studies were included if data on the association between medication adherence and severe asthma exacerbations were presented. Quality was assessed using a modified version of the Newcastle-Ottawa Scale.The search yielded 2319 unique publications, of which 23 met the inclusion criteria and underwent data extraction and quality scoring. High levels of heterogeneity across studies with regard to adherence and exacerbation measurements, designs and analysis precluded a formal meta-analysis. Although effect measures varied widely, good adherence was associated with fewer severe asthma exacerbations in highquality studies.Good adherence tended to be associated with lower risk of severe asthma exacerbations. Future studies should use standardised methodology to assess adherence and exacerbations, and should consider inhaler competence.@ERSpublications High-quality studies indicated that better adherence is associated with fewer severe asthma exacerbations

show abstract

Section: Overview Of the Included Studiesmentioning

confidence: 99%

“…To assess overall treatment adherence, 17 studies used refill data; of these, 11 used MPR measurements [21, 22, 25-29, 31-33, 35] and six used number of prescription refills [23,24,30,34,36,37]. The remaining studies used either electronic monitoring devices (n=3) [9,38,39] or weighted canisters (n=3) [40][41][42].…”

Section: Objective Adherence Measurementsmentioning

confidence: 99%

Medication adherence and the risk of severe asthma exacerbations: a systematic review

et al. 2014

View full text Add to dashboard Cite

show abstract

“…An analysis of the mean change in annual asthma-related utilization rates was conducted for patients from the preindex to the postindex period for each cohort (Table 4) While studies of patients using a single controller therapy have noted significantly less antibiotic use for MON patients, [20][21] no difference in the mean change in antibiotic prescriptions was observed in this study for the ICS/MON (-0.09 claims) vs. ICS/SAL (-0.08 claims).…”

Section: Change In Asthma-related Resource Utilizationmentioning

confidence: 99%

Administrative Claims Analysis of Asthma-Related Health Care Utilization for Patients Who Received Inhaled Corticosteroids With Either Montelukast or Salmeterol as Combination Therapy

Allen‐Ramey¹,

Bukstein²,

Luskin³

et al. 2006

JMCP

View full text Add to dashboard Cite

T FELICIA C. ALLEN-RAMEY, PhD, is senior manager; SHIVA G. SAJJAN, PhD, is manager; and LEONA E. MARKSON, ScD, is executive director, Outcomes Research and Management, Merck & Co., West Point, Pennsylvania; DON BUKSTEIN, MD, is Allen-Ramey, PhD, Senior Manager, Outcomes Research and Management, Merck & Co., Sumneytown Pike, WP39-170, West Point, PA 19486-0004. Tel: (215) Fax: (215) 652-0860; E-mail: felicia_ramey@merck.com Lastly, in a study of symptomatic patients adding SAL or MON to ICS therapy, Fish et al. also report greater improvement in lung function and asthma symptoms among patients adding SAL (morning peak expiratory flow: 35.0 L/min vs. 21.7 L/min; P <0.001; symptom-free days: 24% vs. 16%; P < 0.001). Examination of patients beyond a 12-week period may more closely reflect outcomes seen with chronic use in clinical practice.

show abstract

“…9 The once-a-day oral administration of montelukast seems to lead to greater compliance and satisfaction amongst parents than the use of inhaled corticosteroids, which have to be taken several times a day. 10,11 However, in direct comparative studies with ICS, LTRAs have been shown to be less effective in improving pulmonary function, asthma symptoms, quality of life, asthma attacks, rescue medication and asthma-related costs in asthmatic children older than 6 years of age. 12,13 A Cochrane review of 27 studies in both children and adults confirmed the superior role of ICS compared to LTRAs in asthma.…”

Section: Commentarymentioning

confidence: 99%

Treatment of preschool asthma with leukotriene receptor antagonists: what's new?

Schayk

2007

Primary Care Respiratory Journal

View full text Add to dashboard Cite

“Real-world” effectiveness of daily controller medicine in children with mild persistent asthma

Cited by 69 publications

References 18 publications

Medication adherence and the risk of severe asthma exacerbations: a systematic review

Medication adherence and the risk of severe asthma exacerbations: a systematic review

Administrative Claims Analysis of Asthma-Related Health Care Utilization for Patients Who Received Inhaled Corticosteroids With Either Montelukast or Salmeterol as Combination Therapy

Treatment of preschool asthma with leukotriene receptor antagonists: what's new?

Contact Info

Product

Resources

About